Woodline Partners’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Woodline Partners’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-222,462	Closed	-$2.14M	–	662
2023 Q4	$2.14M	Buy	222,462 +144,427	+185%	+$702K	0.02%	374
2023 Q3	$203K	Buy	+78,035	New	+$250K	﹤0.01%	554
2022 Q2	–	Sell	-25,703	Closed	-$200K	–	914
2022 Q1	$200K	Sell	25,703 -217,637	-89%	-$1.58M	﹤0.01%	552
2021 Q4	$1.01M	Buy	243,340 +88,719	+57%	+$554K	0.01%	502
2021 Q3	$1.23M	Buy	154,621 +24	+0%	+$202	0.02%	488
2021 Q2	$1.25M	Buy	154,597 +30,003	+24%	+$258K	0.02%	413
2021 Q1	$1.34M	Buy	124,594 +71,767	+136%	+$839K	0.03%	343
2020 Q4	$621K	Sell	52,827 -23,266	-31%	-$292K	0.02%	213
2020 Q3	$915K	Sell	76,093 -43,907	-37%	-$600K	0.03%	173
2020 Q2	$2.1M	Buy	+120,000	New	+$2.09M	0.08%	134

Other funds holding FUSN

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners's FUSN Position: Q1 2024 in Review

Woodline Partners sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 222,462 shares — an estimated $2.14M sold.

Woodline Partners first reported a position in FUSN in Q2 2020 and held it in 10 quarters. The position peaked at $2.14M in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

Woodline Partners reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
Woodline Partners sold 222,462 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $2.14M.
Woodline Partners first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 10 quarters.
Woodline Partners's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.14M in Q4 2023.
114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.